You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The researchers suggested that the system's combination of speed and high coverage could enable new applications within the imaging mass spec space.
Fluidigm logged $26.4 million in revenues compared to $29.0 million a year ago and well short of analysts' consensus estimate of $28.7 million.
Revenues rose to $521.1 million from $466.6 million in Q3 2018, beating the consensus Wall Street estimate of $496.7 million.
Waters posted revenues of $577.3 million, short of the average Wall Street estimate of $588.9 million, as soft US pharma sales negatively impacted businesses.
Researchers measured proteins produced by 193 deletions in 136 CRISPR-deleted genes and found residual protein expression in roughly one-third of these cases.
The companies plan to explore opportunities to use Thermo Fisher's LC-MS instrumentation to develop tools to determine the risk for adverse pregnancy outcomes.
The company delivered organic growth across its four business segments and raised its revenue and earnings guidance for the year.
The study is one of several recent efforts to detect bacteria directly with mass spec, which could eliminate the need for culturing and speed turnaround time.
While the approach lost some of its luster after failing to deliver on early hype, technological improvements are revitalizing interest among researchers.
The method could prove useful both for studying tumor immunology and in the development of cancer immunotherapies, said one of the researchers.
The partners will more thoroughly connect Protein Metrics' software suite and Sciex's high-resolution accurate mass (HRAM) spectrometry systems.
Gathering last week in Australia, the community continued its years-long push towards increased clinical relevance and integration with other omics disciplines.
The instrument's ability to run in negative-ion mode allows it to move beyond its traditional focus on proteins and into the analysis of other analyte classes.
Under the agreement, the companies plan to offer combined genetic and biochemical testing services out of Blueprint's clinical laboratory in Seattle.
The approach uses miniaturized sample prep and isobaric tagging and can identify up to 2,300 proteins in single cells and analyze around 100 cells per day.
Under the deal, Mobilion is implementing its SLIM ion mobility technology on Agilent's QTOF mass specs, with a broad commercial launch planned for 2021.
The South San Francisco, California cellular analysis firm alleges IonPath has infringed two patents and has been intereferening in its contracts.
Developed using the center's "industrialized" proteomics workflow, the panel identified patients up to a year before their diagnosis with 89 percent accuracy.
The partners plan to develop a number of liquid chromatography mass spectrometry methods for clinical research applications.
More powerful and user-friendly mass spec systems could drive an uptick in interest in the technique, suggested a leading top-down researcher.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.